Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger (Nasdaq: SDGR) showcased promising preclinical data for its CDC7 inhibitor program at the AACR Annual Meeting on April 10, 2021. The data revealed that the company's picomolar CDC7 inhibitors effectively inhibited tumor cell growth, both individually and in conjunction with existing cancer treatments. The inhibitors demonstrated strong selectivity by inducing cancer cell apoptosis while sparing healthy cells, particularly in mouse models of acute myeloid leukemia and colorectal cancer. Schrödinger plans to advance these findings into IND-enabling studies in 2022.

Schrödinger (Nasdaq: SDGR) announced that its CEO, Ramy Farid, Ph.D., will participate in the BMO BioPharma Spotlight Series on Technology-Enabled Drug Discovery. The virtual panel is scheduled for Friday, April 16, at 10:00 a.m. ET. An on-demand webcast will be available on Schrödinger's website under the 'News & Events' section and will remain accessible for about seven days. Schrödinger is revolutionizing drug and material discovery through its physics-based software platform, which enhances the speed and cost-effectiveness of developing novel therapeutics.

Schrödinger (Nasdaq: SDGR) announced a webcast to review preclinical data from its CDC7 program at the AACR Annual Meeting on April 12, 2021. The session will also cover overviews of internal programs MALT1 and Wee1, highlighting the computational platform's role in drug discovery. Schrödinger's platform aims to accelerate the discovery of high-quality novel molecules, reducing costs compared to traditional methods. This presentation reflects ongoing efforts in drug development and collaboration with various global entities.

Schrödinger (Nasdaq: SDGR) announced CEO Ramy Farid, Ph.D., will participate in a virtual panel during the Credit Suisse 2021 Healthcare Innovators Series on March 23 at 2:00 p.m. ET. The event focuses on the intersection of drug discovery, drug development, and artificial intelligence. An on-demand webcast will be available on Schrödinger's website and archived for about 7 days. Schrödinger aims to transform therapeutic and material discovery through its physics-based software platform, enhancing efficiency and reducing costs for global organizations.

Schrödinger (Nasdaq: SDGR) announced the presentation of preclinical data from its CDC7 program at the AACR Annual Meeting. Targeting CDC7, a protein kinase critical for DNA replication, presents a novel therapeutic approach in cancer treatment. The presentation, titled "Discovery of novel CDC7 inhibitors that disrupt cell cycle dynamics and show anti-proliferative effects in cancer cells," is scheduled for April 10, 2021. Schrödinger’s software platform aids in accelerating the discovery of innovative therapeutics and materials across various sectors.

Schrödinger, Inc. (Nasdaq: SDGR) reported substantial financial results for Q4 and FY 2020, highlighting a 28% revenue growth in Q4, reaching $33 million, with software revenue surging by 42% to $25 million. The company ended 2020 with $643.2 million in cash and equivalents, enabling strategic investments for future growth. Importantly, Schrödinger entered a collaboration with Bristol Myers Squibb, securing a $55 million upfront payment, with potential milestone payments up to $2.7 billion. Looking ahead, the company expects FY 2021 revenue between $124 million and $142 million.

Schrödinger (Nasdaq: SDGR) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The event will feature a virtual corporate overview, which can be accessed via the 'News & Events' section on Schrödinger’s website. This recorded presentation will be available for approximately 14 days.

Schrödinger is revolutionizing drug and materials discovery through its innovative software platform.

Schrödinger, Inc. (Nasdaq: SDGR) has expanded its collaboration with Google Cloud, replacing a three-year agreement with a new five-year deal. This partnership will provide Schrödinger with hundreds of millions of GPU hours, tripling its previous throughput and enhancing its computational capacity for drug discovery and materials science. Schrödinger's Chief Information Officer emphasized this collaboration strengthens their leadership in molecular modeling and drug development. The goal is to accelerate drug discovery, enabling rapid exploration of chemical space.

Schrödinger (Nasdaq: SDGR) will present a corporate overview at the SVB Leerink Partners 10th Annual Global Healthcare Conference on February 26, 2021, at 3:00 p.m. ET. The event will be held virtually, and the live webcast can be accessed via the 'News & Events' section of Schrödinger's website, where it will also be archived for approximately 14 days. Schrödinger's software platform revolutionizes the discovery of therapeutics and materials, enabling faster and more cost-effective drug development.